Omega Fund

Omega Fund Management / Omega Funds is a U.S. sector-specialist biotechnology and medical-device private equity / venture capital firm founded in 2004 and headquartered in Boston, Massachusetts (with additional presence in San Francisco and London). The firm invests in biotechnology and medical-device firms across North America and Western Europe, focusing on early-stage through pre-IPO / crossover investments. Omega Funds was founded by Founder and Managing Partner Otello Stampacchia (Italian-origin biotech-industry veteran; PhD from University of Geneva; prior roles at AGT Capital and Index Ventures), alongside partners including Anne-Mari Paster (Managing Director), Andrew Sinclair (General Partner), Richard Lim (Managing Director), Francesco Draetta, and Claudio Nessi. The firm has raised multiple institutional funds (Omega Fund I through Omega Fund VII), with aggregate AUM approaching USD 2 billion+ across vintages, typically writing initial check sizes in the USD 5 to 40 million range with flexibility across preferred-equity, convertible-debt, and public-market crossover structures. Notable portfolio companies include Editas Medicine (NASDAQ: EDIT), bluebird bio (NASDAQ: BLUE), Aduro Biotech (acquired by Chinook Therapeutics / Novartis), Principia Biopharma (acquired by Sanofi for USD 3.7 billion in 2020), Nuvation Bio, Century Therapeutics, and many other leading biotechnology companies producing multiple IPOs and M&A exits.